Seminars in Radiation Oncology
Volume 18, Issue 1 , Pages 7-14 , January 2008

Hormone Therapy and Radiotherapy for Intermediate Risk Prostate Cancer

  • Irwin Lee, MD, PhD
    • ,
  • Howard Sandler, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Howard Sandler, MD, 1500 Medical Center Drive, Ann Arbor, MI 48109-5010.

References 

  1. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33
  2. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168:9–12
  3. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:15–23
  4. Joon DL, Hasegawa M, Sikes C, et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 1997;38:1071–1077
  5. Zietman AL, Nakfoor BM, Prince EA, et al. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study. Cancer J Sci Am. 1997;3:31–36
  6. Zietman AL, Prince EA, Nakfoor BM, et al. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 1997;38:1067–1070
  7. Lilleby W, Fossa SD, Knutsen BH, et al. Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother Oncol. 2000;57:195–200
  8. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA. 1997;277:1445–1451
  9. D’Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440–447
  10. Lee AK, Schultz D, Renshaw AA, et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys. 2001;49:673–677
  11. Beard C, Schultz D, Loffredo M, et al. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:403–407
  12. Lee IH, Roberts R, Shah RB, et al. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:1059–1064
  13. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  14. Stock RG, Ho A, Cesaretti JA, et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys. 2006;66:389–394
  15. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15:1013–1021
  16. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  17. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet. 2002;360:103–106
  18. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–3978
  19. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  20. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  21. D’Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280–1283
  22. D’Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827
  23. Valicenti RK, Bae K, Michalski J, et al. In: Does adjuvant hormonal therapy improve freedom from biochemical relapse in prostate cancer patients receiving dose-escalated radiation therapy? (An analysis of RTOG 94-06). ASCO Prostate Cancer Symposium, Abstract 297, Orlando, FL, February 22–24. 2007;
  24. Dearnaley DP, Sydes MR, Morgan RC, et al. In: Early efficacy and late toxicity of escalated-over-standard-dose conformal radiotherapy with neo-adjuvant androgen suppression for men with localized prostate cancer: First results of MRC RT01 trial (ISRCTN47772397). ASCO Prostate Cancer Symposium, Abstract 295, Orlando, FL, February 22–24. 2007;
  25. Stephens RJ, Dearnaley DP, Cowan R, et al. The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: Data from the Medical Research Council RT01 trial (ISRCTN 47772397). BJU Int. 2007;99:301–310
  26. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164
  27. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  28. Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol. 2005;173:1567–1571
  29. Murthy V, Norman AR, Shahidi M, et al. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int. 2006;97:476–479
  30. Feigenberg SJ, Hanlon AL, Horwitz EM, et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:397–405
  31. Christie D, Denham J, Steigler A, et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol. 2005;77:117–125
  32. Valicenti RK, Winter K, Cox JD, et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?. Int J Radiat Oncol Biol Phys. 2003;57:614–620

PII: S1053-4296(07)00074-4

doi: 10.1016/j.semradonc.2007.09.002

Seminars in Radiation Oncology
Volume 18, Issue 1 , Pages 7-14 , January 2008

Article Tools